UC
MCID: ULC004
MIFTS: 73

Ulcerative Colitis (UC)

Categories: Gastrointestinal diseases

Aliases & Classifications for Ulcerative Colitis

MalaCards integrated aliases for Ulcerative Colitis:

Name: Ulcerative Colitis 12 74 25 36 42 15 37 17 71 32
Inflammatory Bowel Disease, Ulcerative Colitis Type 25
Chronic Left-Sided Ulcerative Colitis 71
Left-Sided Ulcerative Colitis 12
Left Sided Ulcerative Colitis 71
Idiopathic Proctocolitis 25
Colitis, Ulcerative 43
Colitis Ulcerative 54
Colitis Gravis 25
Uc 25

Classifications:



External Ids:

Disease Ontology 12 DOID:8577
KEGG 36 H01466
ICD9CM 34 556 556.5 556.9
MeSH 43 D003093
NCIt 49 C2952
ICD10 32 K51 K51.9
UMLS 71 C0009324 C0375359 C2919576

Summaries for Ulcerative Colitis

Genetics Home Reference : 25 Ulcerative colitis is a chronic disorder that affects the digestive system. This condition is characterized by abnormal inflammation of the inner surface of the rectum and colon, which make up most of the length of the large intestine. The inflammation usually causes open sores (ulcers) to develop in the large intestine. Ulcerative colitis usually appears between ages 15 and 30, although it can develop at any age. The inflammation tends to flare up multiple times throughout life, which causes recurring signs and symptoms. The most common symptoms of ulcerative colitis are abdominal pain and cramping and frequent diarrhea, often with blood, pus, or mucus in the stool. Other signs and symptoms include nausea, loss of appetite, fatigue, and fevers. Chronic bleeding from the inflamed and ulcerated intestinal tissue can cause a shortage of red blood cells (anemia) in some affected individuals. People with this disorder have difficulty absorbing enough fluids and nutrients from their diet and often experience weight loss. Affected children usually grow more slowly than normal. Less commonly, ulcerative colitis causes problems with the skin, joints, eyes, kidneys, or liver, which are most likely due to abnormal inflammation. Toxic megacolon is a rare complication of ulcerative colitis that can be life-threatening. Toxic megacolon involves widening of the colon and an overwhelming bacterial infection (sepsis). Ulcerative colitis also increases the risk of developing colon cancer, especially in people whose entire colon is inflamed and in people who have had ulcerative colitis for 8 or more years. Ulcerative colitis is one common form of inflammatory bowel disease (IBD). Another type of IBD, Crohn disease, also causes chronic inflammation of the intestines. Unlike ulcerative colitis, which affects only the inner surface of the large intestine, Crohn disease can cause inflammation in any part of the digestive system, and the inflammation extends deeper into the intestinal tissue.

MalaCards based summary : Ulcerative Colitis, also known as inflammatory bowel disease, ulcerative colitis type, is related to inflammatory bowel disease 1 and pouchitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Ulcerative Colitis is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and JAK-STAT signaling pathway. The drugs Copper and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include Bone, colon and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12

MedlinePlus : 42 Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

KEGG : 36 Ulcerative colitis (UC) is one subtype of inflammatory bowel disease (IBD) whose pathogenesis is multifactorial and includes influences from genes, the environment, and the gut microbiome. In UC the inflammatory is limited to the musoca of the colon and rectum. Clinically, the most common manifestation of UC may include bloody diarrhea, abdominal pain. In most severe cases, patients may experience fever, weight loss, anemia, and the intestine can get distended, presenting deep ulceration and possibly intestinal perforation.The long-time duration of the disease increases a colorectal caner risk. UC is associated with a Th2 immune response. Recent genetic analyses have linked genes including interleukin 23 receptor, interleukin 10 and macrophage stimulating 1.

Wikipedia : 74 Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon... more...

Related Diseases for Ulcerative Colitis

Diseases related to Ulcerative Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1307)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 1 34.5 TNF NOD2 IRGM IL23R ATG16L1
2 pouchitis 33.7 NOD2 CXCL8
3 pyoderma gangrenosum 33.7 TNF NOD2 CXCL8
4 chemical colitis 33.5 TNF NOD2 IL10
5 irritable bowel syndrome 33.5 TNF IL10 CXCL8
6 crohn's disease 33.4 TNF NOD2 IRGM IL23R IL2 IL1B
7 inflammatory bowel disease 33.2 TNF REG4 NOD2 MPO MLH1 IRGM
8 inflammatory bowel disease 25, autosomal recessive 33.1 IL10RA IL10
9 proctitis 32.5 TNF MPO ABCB1
10 crohn's colitis 32.5 TNF NOD2 IL2 IL1B CXCL8
11 colitis 32.5 UCN TNF REG4 NOD2 MSH2 MPO
12 pyoderma 32.4 TNF NOD2 CXCL8
13 cholangitis 32.4 TNF NOD2 MPO IL2 IL10 HLA-DRB1
14 sclerosing cholangitis 32.3 TNF NOD2 MPO IL2 IL10 HLA-DRB1
15 diarrhea 32.2 TNF MPO IL2 IL1B IL10 CXCL8
16 cytomegalovirus infection 32.1 TNF IL1B CXCL8
17 ileitis 32.0 TNF NOD2 MPO IL10 ATG16L1
18 autoimmune disease 31.9 TNF IL23R IL2 IL1B IL10 HLA-DRB1
19 spondylitis 31.9 TNF NOD2 IL23R IL10
20 allergic hypersensitivity disease 31.8 TNF IL2 IL10 CXCL8
21 proteasome-associated autoinflammatory syndrome 1 31.8 TNF MPO IL1B IL10 CXCL8
22 dysentery 31.8 TNF IL1B IL10 CXCL8
23 exanthem 31.8 TNF IL2 IL10 CXCL8
24 gastritis 31.7 TNF IL1B IL10 CXCL8
25 pericarditis 31.7 TNF IL1B CXCL8
26 sarcoidosis 1 31.7 TNF NOD2 IL2 IL1B HLA-DRB1
27 hypereosinophilic syndrome 31.7 MPO IL2 IL10 CXCL8
28 bronchiolitis 31.7 TNF IL10 CXCL8
29 microscopic colitis 31.7 TNF IL2 HLA-DRB1
30 uveitis 31.7 TNF NOD2 IL2 IL10 CXCL8
31 acute pancreatitis 31.7 TNF MPO IL1B IL10 CXCL8
32 thyroiditis 31.7 TNF IL2 IL10
33 dermatitis 31.7 TNF NOD2 IL2 IL10 CXCL8
34 ileocolitis 31.6 TNF NOD2 ATG16L1
35 spondyloarthropathy 1 31.6 TNF NOD2 IL23R
36 myocarditis 31.6 TNF IL2 IL1B IL10
37 peptic ulcer disease 31.6 TNF IL1B IL10 CXCL8
38 herpes zoster 31.6 TNF IL2 IL10 HLA-DRB1
39 aortitis 31.6 TNF NOD2 MPO
40 ileus 31.6 TNF IL1B IL10
41 takayasu arteritis 31.6 TNF IL2 IL10 HLA-DRB1
42 arthritis 31.6 TNF NOD2 IL1B IL10 HLA-DRB1 CXCL8
43 primary biliary cirrhosis 31.6 TNF IL2 IL1B IL10 HLA-DRB1
44 appendicitis 31.6 TNF MPO IL2 IL1B IL10 CXCL8
45 autoimmune pancreatitis 31.5 TNF IL10 HLA-DRB1
46 psoriasis 31.5 TNF NOD2 IL23R IL2 IL1B IL10
47 celiac disease 1 31.5 TNF NOD2 IL23R IL2 IL10 HLA-DRB1
48 anal fistula 31.5 TNF MSH2 MLH1
49 bronchiolitis obliterans 31.5 TNF MPO IL10 CXCL8
50 esophagitis 31.5 TNF IL1B IL10 CXCL8

Comorbidity relations with Ulcerative Colitis via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Crohn's Disease Deficiency Anemia
Esophagitis Hypothyroidism
Inflammatory Bowel Disease 1 Intestinal Obstruction
Iron Deficiency Anemia Paralytic Ileus
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ulcerative Colitis:



Diseases related to Ulcerative Colitis

Symptoms & Phenotypes for Ulcerative Colitis

UMLS symptoms related to Ulcerative Colitis:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Ulcerative Colitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 CXCL8 IL10 IL1B IL2 MLH1 MPO
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 CXCL8 IL10 IL1B IL2 MLH1 MPO

MGI Mouse Phenotypes related to Ulcerative Colitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 ABCB1 ATG16L1 IL10 IL10RA IL1B IL2
2 digestive/alimentary MP:0005381 10.02 ABCB1 ATG16L1 IL10 IL10RA IL2 IL23R
3 homeostasis/metabolism MP:0005376 9.97 ABCB1 ATG16L1 IL10 IL10RA IL1B IL2
4 immune system MP:0005387 9.73 ABCB1 ATG16L1 IL10 IL10RA IL1B IL2
5 neoplasm MP:0002006 9.17 IL10 IL1B IL2 IL23R MLH1 MSH2

Drugs & Therapeutics for Ulcerative Colitis

Drugs for Ulcerative Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 407)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Copper Approved, Investigational Phase 4 7440-50-8 27099
2
Adalimumab Approved Phase 4 331731-18-1 16219006
3
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
4
Linaclotide Approved Phase 4 851199-59-2 65351
5
Tofacitinib Approved, Investigational Phase 4 477600-75-2
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
7
Nicotine Approved Phase 4 54-11-5 942 89594
8
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
9
Losartan Approved Phase 4 114798-26-4 3961
10
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
11
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
12
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
13
Caffeine Approved Phase 4 58-08-2 2519
14
Magnesium citrate Approved Phase 4 3344-18-1
15
carbamide peroxide Approved Phase 4 124-43-6
16
Vancomycin Approved Phase 4 1404-90-6 441141 14969
17
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
18
Ustekinumab Approved, Investigational Phase 4 815610-63-0
19
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
20
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
21 Nutrients Phase 4
22 Trace Elements Phase 4
23 Micronutrients Phase 4
24 Vitamins Phase 4
25 Iron Supplement Phase 4
26 Cyclosporins Phase 4
27 Hematinics Phase 4
28 Ferric Oxide, Saccharated Phase 4
29 Protein Kinase Inhibitors Phase 4
30 Anti-Ulcer Agents Phase 4
31 Antacids Phase 4
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
33 Chelating Agents Phase 4
34 Proton Pump Inhibitors Phase 4
35 Antihypertensive Agents Phase 4
36 Anti-Arrhythmia Agents Phase 4
37 Hypnotics and Sedatives Phase 4
38 Central Nervous System Stimulants Phase 4
39 Adjuvants, Anesthesia Phase 4
40 Anesthetics, General Phase 4
41 GABA Agents Phase 4
42 Angiotensin II Type 1 Receptor Blockers Phase 4
43 GABA Modulators Phase 4
44 Antitussive Agents Phase 4
45 Anesthetics, Intravenous Phase 4
46 Giapreza Phase 4
47 Angiotensin Receptor Antagonists Phase 4
48 Phosphodiesterase Inhibitors Phase 4
49 Angiotensinogen Phase 4
50 Picosulfate sodium Phase 4

Interventional clinical trials:

(show top 50) (show all 1251)
# Name Status NCT ID Phase Drugs
1 PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis - A Randomised Controlled Trial Unknown status NCT02770040 Phase 4 Infliximab
2 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
3 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis: An Open-label,Randomized,Phase IV Clinical Trial Unknown status NCT02962245 Phase 4 berberine;regular treatment
4 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
5 Pilot Study to Evaluate the Efficacy of Golimumab for Induction and Maintenance of Clinical and Endoscopic Remission in Patients With Steroid-dependent Ulcerative Colitis Unknown status NCT02412085 Phase 4 Golimumab
6 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
7 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
8 Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis. Unknown status NCT01941589 Phase 4 oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;corticosteroids only
9 A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC) Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
10 Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial Unknown status NCT01479660 Phase 4 Probiotic
11 Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi) Unknown status NCT02186886 Phase 4 Golimumab
12 A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology Unknown status NCT02910375 Phase 4
13 The Effect of Probiotics on Bowel Disease Unknown status NCT01078935 Phase 4
14 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
15 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
16 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
17 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
18 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
19 Preference for a Prefilled Syringe or Smartject™ Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
20 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
21 Multicentre Investigation of the Efficacy and Safety of Adacolumn® GMA in Patients With Steroid-Dependent Active Ulcerative Colitis and Insufficient Response or Intolerance to Immunosuppressants and/or Biological Therapies Completed NCT01481142 Phase 4
22 An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically Completed NCT02559713 Phase 4 Vedolizumab
23 An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab. Completed NCT02318667 Phase 4
24 A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
25 Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis Completed NCT02092285 Phase 4 Golimumab
26 A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
27 Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
28 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
29 A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
30 Histological and Endoscopic Evaluation of Remission Induced by Infliximab in Moderately to Severely Active Ulcerative Colitis Patients Completed NCT01408810 Phase 4 Infliximab
31 Test Treat Strategy to Prevent Ulcerative Colitis Relapse Completed NCT00652145 Phase 4 mesalamine
32 Multi Center Ulcerative Colitis Pediatric Pentasa Intervention Trial (MUPPIT). A Randomized, Single-blinded, Controlled, Parallel, Induction Therapy With Once vs. Twice Daily Dosing of Pentasa in Pediatric UC. Completed NCT01201122 Phase 4 Mesalamine
33 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
34 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
35 Multicenter Open-label Study Evaluating the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine to Treat Children and Adolescents With Newly Diagnosed Ulcerative Colitis. Completed NCT01536535 Phase 4 Mesalazine;IV Corticosteroid;Oral Corticosteroids
36 Open Label Safety and Efficacy Trial of Twice Daily Dosing of Asacol vs. Three Times Per Day Dosing for the Induction of Remission in Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)
37 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
38 A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
39 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
40 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
41 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
42 Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
43 Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients Completed NCT02461758 Phase 4
44 Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission Completed NCT02453776 Phase 4 PRECISION dosing Infliximab
45 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
46 Randomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's Disease Completed NCT00114465 Phase 4 VSL#3
47 Improving Multivitamin Supplementation to Pregnant Women Completed NCT02300155 Phase 4 Pregvit®;Orifer F®
48 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
49 Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial Completed NCT02256462 Phase 4 Adalimumab
50 A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose

Search NIH Clinical Center for Ulcerative Colitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Azathioprine
balsalazide
Balsalazide disodium
Hydrocortisone
hydrocortisone acetate
HYDROCORTISONE ACETATE PWDR
HYDROCORTISONE ACETONIDE
Hydrocortisone butyrate
hydrocortisone cypionate
hydrocortisone probutate
HYDROCORTISONE PWDR
Hydrocortisone sodium phosphate
Hydrocortisone sodium succinate
hydrocortisone valerate
HYDROCORTISONE,NONSTERILE PWDR
mesalamine
nicotine polacrilex
olsalazine
Olsalazine sodium
Psyllium
PSYLLIUM HYDROCOLLOID
Sulfasalazine

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Ulcerative Colitis cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: colitis, ulcerative

Genetic Tests for Ulcerative Colitis

Anatomical Context for Ulcerative Colitis

MalaCards organs/tissues related to Ulcerative Colitis:

40
Colon, Liver, T Cells, Testes, Neutrophil, Bone, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Ulcerative Colitis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Ulcerative Colitis

Articles related to Ulcerative Colitis:

(show top 50) (show all 30243)
# Title Authors PMID Year
1
Elective Abdominal Surgery for Inflammatory Bowel Disease. 61 42
31676052 2019
2
Ileal Pouch Complications. 42
31676057 2019
3
Association of Glutathione S-Transferase M1 null genotype with inflammatory bowel diseases: A systematic review and meta-analysis. 42
31689810 2019
4
TNFalpha is a key mediator of the pronociceptive effects of mucosal supernatant from human ulcerative colitis on colonic DRG neurons. 54 61
20427396 2010
5
STAT4 gene influences genetic predisposition to ulcerative colitis but not Crohn's disease in the Spanish population: a replication study. 54 61
20153791 2010
6
High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis. 54 61
19714749 2010
7
Delayed resolution of acute inflammation in ulcerative colitis is associated with elevated cytokine release downstream of TLR4. 54 61
20360984 2010
8
Involvement of the IL-22/REG Ialpha axis in ulcerative colitis. 54 61
20065946 2010
9
MICB0106 gene polymorphism is associated with ulcerative colitis in central China. 54 61
19662431 2010
10
Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. 54 61
19926618 2010
11
Assessment of Growth Disturbance in Japanese Children with IBD. 54 61
20454571 2010
12
A new natural angelica polysaccharide based colon-specific drug delivery system. 54 61
19408300 2009
13
Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. 54 61
19958093 2009
14
Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. 54 61
19632232 2009
15
The relationship between the expression of the glucocorticoid receptor in biopsied colonic mucosa and the glucocorticoid responsiveness of ulcerative colitis patients. 54 61
19646928 2009
16
Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. 54 61
20136960 2009
17
[IL-6 and TNF-α gene expression in the rectal mucosal of patients with chronic idiopathic ulcerative colitis and controls]. 54 61
20423763 2009
18
Decreased Toll-like receptor-5 (TLR-5) expression in the mucosa of ulcerative colitis patients. 54 61
20083854 2009
19
Down-regulation of protein and mRNA expression of IL-8 and ICAM-1 in colon tissue of ulcerative colitis patients by partition-herb moxibustion. 54 61
19083096 2009
20
Frequency of single nucleotide polymorphisms in NOD1 gene of ulcerative colitis patients: a case-control study in the Indian population. 54 61
19723304 2009
21
HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease. 54 61
19758229 2009
22
Reduction of interleukin-6, interleukin-8, and anti-phosphatidylserine-prothrombin complex antibody by granulocyte and monocyte adsorption apheresis in a patient with pyoderma gangrenosum and ulcerative colitis. 54 61
19727102 2009
23
Genetics of ulcerative colitis: the come-back of interleukin 10. 54 61
19671546 2009
24
DNA-driven nutritional therapy of inflammatory bowel disease. 54 61
19647622 2009
25
DNA-bound lactoferrin is the major target for antineutrophil perinuclear cytoplasmic antibodies in ulcerative colitis. 54 61
19758145 2009
26
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. 54 61
19408340 2009
27
[The cytokines in inflammatory bowel disease]. 54 61
19724079 2009
28
In situ evidence of involvement of Schwann cells in ulcerative colitis: autocrine and paracrine signaling by A disintegrin and metalloprotease-17-mediated tumor necrosis factor alpha production. 54 61
19376560 2009
29
Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. 54 61
19592695 2009
30
[Association of cytotoxic T lymphocyte antigen-4 promoter C-658T polymorphism with ulcerative colitis in Chinese]. 54 61
20017310 2009
31
Nuclear pregnane X receptor single nucleotide polymorphism (-25385C/T) is not associated with inflammatory bowel disease in pediatric patients. 54 61
19516190 2009
32
Genetic polymorphisms of interleukin 8 and risk of ulcerative colitis in the Chinese population. 54 61
19348790 2009
33
Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. 54 61
19528350 2009
34
The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. 54 61
19694343 2009
35
Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves. 54 61
19617644 2009
36
The combination of polymorphisms within MCP-1 and IL-1beta associated with ulcerative colitis. 54 61
19392835 2009
37
PPARgamma agonists as a new class of effective treatment for ulcerative colitis. 54 61
18798571 2009
38
Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). 54 61
19184329 2009
39
GlcNAc6ST-1-mediated decoration of MAdCAM-1 protein with L-selectin ligand carbohydrates directs disease activity of ulcerative colitis. 54 61
19067429 2009
40
Cytotoxic T lymphocyte antigen-4 promoter -658CT gene polymorphism is associated with ulcerative colitis in Chinese patients. 54 61
19089435 2009
41
Epithelial tight junctions in intestinal inflammation. 54 61
19538319 2009
42
[TNF alfa polymorphism and course of ulcerative colitis]. 54 61
19606693 2009
43
I219V polymorphism in hMLH1 gene in patients affected with ulcerative colitis. 54 61
19371218 2009
44
Effect of MDR1 gene promoter methylation in patients with ulcerative colitis. 54 61
19288029 2009
45
Interleukin 10 promoter region polymorphisms in inflammatory bowel disease in Tunisian population. 54 61
19184348 2009
46
Immune response and gene polymorphism profiles in Crohn's disease and ulcerative colitis. 54 61
18942754 2009
47
Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease. 54 61
18942752 2009
48
Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. 54 61
19294580 2009
49
Correlation of plasma MMP-1 and TIMP-1 levels and the colonic mucosa expressions in patients with ulcerative colitis. 54 61
19911067 2009
50
[Susceptibility genetic variants in Hungarian morbus Crohn and ulcerative colitis patients]. 54 61
19103559 2009

Variations for Ulcerative Colitis

Expression for Ulcerative Colitis

LifeMap Discovery
Genes differentially expressed in tissues of Ulcerative Colitis patients vs. healthy controls: 35 (show all 12)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CLDN8 claudin 8 Colon - 4.72 0.000
2 LCN2 lipocalin 2 Colon + 4.60 0.000
3 REG3A regenerating islet-derived 3 alpha Colon + 4.41 0.001
4 SLC26A2 solute carrier family 26 (anion exchanger), member 2 Colon - 4.19 0.000
5 PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) Colon - 4.13 0.000
6 CXCL8 chemokine (C-X-C motif) ligand 8 Colon + 3.86 0.003
7 CXCL2 chemokine (C-X-C motif) ligand 2 Colon + 3.85 0.000
8 REG1A regenerating islet-derived 1 alpha Colon + 3.68 0.005
9 RGS3 regulator of G-protein signaling 3 Colon + 3.58 0.000
10 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) Colon + 3.55 0.000
11 OLFM4 olfactomedin 4 Colon + 3.25 0.014
12 DEFA6 defensin, alpha 6, Paneth cell-specific Colon + 3.22 0.003
Search GEO for disease gene expression data for Ulcerative Colitis.

Pathways for Ulcerative Colitis

Pathways related to Ulcerative Colitis according to KEGG:

36
# Name Kegg Source Accession
1 Cytokine-cytokine receptor interaction hsa04060
2 JAK-STAT signaling pathway hsa04630
3 Inflammatory bowel disease (IBD) hsa05321

Pathways related to Ulcerative Colitis according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.31 TNF NOD2 IL23R IL2 IL1B IL10RA
2
Show member pathways
13.29 TNF IL23R IL2 IL1B IL10RA IL10
3
Show member pathways
13.1 TNF NOD2 IL2 IL1B IL10 CXCL8
4
Show member pathways
12.81 TNF IL2 IL1B IL10 HLA-DRB1 CXCL8
5
Show member pathways
12.8 TNF IL2 IL1B HLA-DRB1 CXCL8
6
Show member pathways
12.62 TNF IL2 IL10RA IL10 HLA-DRB1
7 12.55 TNF MPO IL2 IL1B IL10
8
Show member pathways
12.45 TNF NOD2 IL23R IL2 IL1B IL10
9 12.36 TNF IL1B CXCL8 ATG16L1
10
Show member pathways
12.33 IL23R IL2 IL10RA IL10
11
Show member pathways
12.33 TNF IL2 IL10RA IL10 CXCL8
12
Show member pathways
12.32 TNF MPO IL2 IL1B
13
Show member pathways
12.26 TNF IL2 IL1B IL10 CXCL8
14 12.21 TNF NOD2 IL1B CXCL8 ATG16L1
15
Show member pathways
12.2 TNF IL2 IL1B IL10
16 12.17 TNF IL1B IL10 CXCL8
17
Show member pathways
12.16 TNF IRGM IL1B IL10RA IL10 HLA-DRB1
18
Show member pathways
12.09 TNF MSH2 MPO IL23R IL2 IL1B
19 12.01 TNF IL2 IL1B CXCL8
20
Show member pathways
12.01 TNF IL23R IL2 IL1B IL10
21 11.99 TNF MPO IL2 IL10
22 11.99 TNF NOD2 IL1B IL10RA IL10 HLA-DRB1
23 11.95 TNF IL2 IL1B IL10 CXCL8
24 11.92 TNF IL1B IL10 CXCL8
25 11.91 TNF IL23R IL1B IL10 CXCL8
26 11.89 IL23R IL2 IL10RA IL10
27 11.87 TNF IL1B HLA-DRB1 CXCL8
28 11.77 TNF IL1B IL10 CXCL8
29 11.75 TNF IL2 IL1B IL10
30
Show member pathways
11.74 TNF IL2 CXCL8
31 11.72 TNF IL2 IL1B IL10
32 11.65 TNF IL1B CXCL8
33
Show member pathways
11.64 TNF IL2 IL1B CXCL8
34 11.62 TNF IL23R IL2 IL1B IL10
35 11.6 TNF IL1B CXCL8
36 11.52 TNF IL2 IL1B
37 11.51 TNF IL1B IL10 CXCL8
38
Show member pathways
11.42 MSH2 MLH1 ABCB1
39 11.38 TNF IL1B IL10
40 11.28 TNF IL1B IL10RA IL10
41 11.26 MSH2 MPO MLH1
42 11.24 TNF IL1B IL10RA IL10 CXCL8
43 10.96 TNF MPO IL1B
44 10.48 TNF IL2 IL1B IL10 HLA-DRB1

GO Terms for Ulcerative Colitis

Cellular components related to Ulcerative Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 8.62 MSH2 MLH1

Biological processes related to Ulcerative Colitis according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.04 TNF IL2 IL1B IL10 HLA-DRB1 CXCL8
2 defense response to bacterium GO:0042742 9.92 TNF NOD2 MPO IRGM IL10
3 positive regulation of protein phosphorylation GO:0001934 9.88 UCN TNF IRGM IL2 IL1B
4 positive regulation of inflammatory response GO:0050729 9.86 TNF IL2 IL1B
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.86 UCN TNF IRGM
6 positive regulation of JNK cascade GO:0046330 9.85 TNF NOD2 IL1B
7 response to lipopolysaccharide GO:0032496 9.85 MPO IL23R IL1B IL10RA IL10
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 TNF IL23R IL2
9 cellular response to organic cyclic compound GO:0071407 9.83 TNF NOD2 IL1B
10 response to glucocorticoid GO:0051384 9.83 UCN TNF IL10
11 positive regulation of T cell proliferation GO:0042102 9.82 IL23R IL2 IL1B
12 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.82 TNF NOD2 IL1B
13 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.8 TNF MSH2 MLH1
14 defense response GO:0006952 9.77 TNF NOD2 MPO IRGM CXCL8
15 positive regulation of JAK-STAT cascade GO:0046427 9.73 TNF IL10RA IL10
16 regulation of synapse organization GO:0050807 9.72 TNF IL10RA IL10
17 positive regulation of interleukin-8 production GO:0032757 9.71 TNF NOD2 IL1B
18 positive regulation of interleukin-6 production GO:0032755 9.71 UCN TNF NOD2 IL1B
19 inflammatory response GO:0006954 9.7 UCN TNF IRGM IL23R IL1B IL10
20 positive regulation of neuroinflammatory response GO:0150078 9.68 TNF IL1B
21 response to molecule of bacterial origin GO:0002237 9.68 IL10 CXCL8
22 positive regulation of chemokine biosynthetic process GO:0045080 9.67 TNF IL1B
23 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.67 IL23R IL1B
24 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 TNF IL1B IL10
25 detection of bacterium GO:0016045 9.66 NOD2 HLA-DRB1
26 endothelial cell apoptotic process GO:0072577 9.65 TNF IL10
27 regulation of establishment of endothelial barrier GO:1903140 9.64 TNF IL1B
28 nucleotide-binding oligomerization domain containing 2 signaling pathway GO:0070431 9.63 NOD2 IRGM
29 negative regulation of cytokine secretion involved in immune response GO:0002740 9.63 TNF IL10
30 positive regulation of isotype switching to IgA isotypes GO:0048298 9.62 MSH2 MLH1
31 positive regulation of fever generation GO:0031622 9.61 TNF IL1B
32 somatic recombination of immunoglobulin gene segments GO:0016447 9.61 MSH2 MLH1
33 positive regulation of interleukin-17 production GO:0032740 9.61 NOD2 IL23R IL2
34 protein lipidation involved in autophagosome assembly GO:0061739 9.6 IRGM ATG16L1
35 sequestering of triglyceride GO:0030730 9.59 TNF IL1B
36 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 TNF IL1B
37 receptor biosynthetic process GO:0032800 9.58 TNF IL10
38 positive regulation of interferon-gamma production GO:0032729 9.56 TNF IL23R IL2 IL1B
39 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.51 MSH2 MLH1
40 positive regulation of isotype switching to IgG isotypes GO:0048304 9.5 MSH2 MLH1 IL2
41 cellular response to lipopolysaccharide GO:0071222 9.43 TNF NOD2 IRGM IL1B IL10 CXCL8
42 cytokine-mediated signaling pathway GO:0019221 9.17 TNF IL23R IL2 IL1B IL10RA IL10

Molecular functions related to Ulcerative Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatched DNA binding GO:0030983 9.16 MSH2 MLH1
2 cytokine activity GO:0005125 9.02 TNF IL2 IL1B IL10 CXCL8
3 guanine/thymine mispair binding GO:0032137 8.96 MSH2 MLH1

Sources for Ulcerative Colitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....